Physician profile
Angela Conley
NPI 1407376734
$4,326.28
in general payments reported to CMS, 2019-2025
31 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $633 · 2024: $1,983 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,307 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,307.43 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $624.35 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $572.14 | 2023-2025 | Farxiga, Airsupra |
| Abbvie INC. | $565.98 | 2023-2025 | |
| Novo Nordisk INC | $271.08 | 2023-2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $261.45 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.87 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $204.25 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $202.46 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.64 | 2024-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $159.21 | 2023-2025 | Mounjaro, Zepbound |
| Actelion Pharmaceuticals US, INC. | $153.03 | 2023-2024 | Opsumit, Uptravi |
| Lundbeck LLC | $133.19 | 2023-2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $106.46 | 2024 | Inpefa |
| Exact Sciences Corporation | $79.24 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $71.74 | 2024 | Evenity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $66.68 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.46 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $50.40 | 2024-2025 | |
| Almatica Pharma LLC | $42.76 | 2023-2024 | Loreev Xr |
| Astellas Pharma US INC | $38.91 | 2023-2024 | Veozah |
| Inspire Medical Systems, INC. | $32.00 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $30.00 | 2023-2024 | Verquvo, Capvaxive, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $28.47 | 2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $24.88 | 2025 | Austedo Xr |
| Glaxosmithkline, LLC. | $22.92 | 2025 | Shingrix |
| Pacira Pharmaceuticals Incorporated | $19.72 | 2023 | Exparel, Iovera, Zilretta |
| Grifols USA, LLC | $19.14 | 2024 | Prolastin-C Liquid |
| Convatec INC. | $17.07 | 2024 | |
| Viatris Specialty LLC | $16.05 | 2025 | Yupelri |
| Seqirus USA INC | $15.66 | 2025 | Flucelvax, Fluad |
| Mylan Specialty L.P. | $13.07 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.